\n<\/p>\n
Dr\u00e4gerwerk AG & Co. KGaA (ETR:DRW3) outlined its current positioning and financial priorities during a presentation at a German Select Conference, with Head of Treasury and Investor Relations Thomas Fischler highlighting the company\u2019s two-division structure, recent earnings momentum, and growth opportunities in hospital interoperability and defense-related safety equipment.<\/p>\n
Fischler said Dr\u00e4ger\u2019s business is anchored in its \u201cTechnology for Life\u201d philosophy, describing the company\u2019s portfolio as focused on products that \u201cprotect, support, and save lives.\u201d He noted the group operates in two divisions\u2014Medical and Safety\u2014with an approximate 60\/40 split in net sales.<\/p>\n
\u2192 3 Surprising S&P 500 Outperformers of 2026<\/a><\/p>\n Geographically, Fischler said around 20% of net sales are generated in Germany, with Europe and the Middle East representing about 40%. The Americas account for a significant portion as well, including roughly $450 million of net sales in the U.S., while Asia Pacific is the smallest reporting region at 16%.<\/p>\n He added that about 60% of employees are customer-facing, with roughly 20% in production, quality, and logistics, and about 10% each in R&D and administration. Dr\u00e4ger sells in \u201cbasically every country,\u201d he said, with its own subsidiaries in about 50 countries. Production and development sites are concentrated in a smaller number of locations, including L\u00fcbeck as the largest, a U.S. facility for patient monitoring, SCBA manufacturing in the U.K., and China operations designed to serve local-content requirements. Fischler said the company is also building a new facility in India intended to develop and produce products for that fast-growing market and similar markets in the region.<\/p>\n \u2192 Microsoft\u2019s Copilot Problem Isn\u2019t What You Think<\/a><\/p>\n Within the Medical division, Fischler said Dr\u00e4ger targets high-acuity areas of hospitals such as operating rooms and intensive care units, rather than lower-acuity wards. He identified anesthesia and ventilation as the largest franchises by sales and earnings, followed by workplace infrastructure products and thermoregulation (including incubators). Aftersales\u2014services and consumables\u2014accounts for roughly \u201c40 and above percent\u201d of Medical division net sales depending on the year, he said.<\/p>\n Patient monitoring is a smaller business where Dr\u00e4ger is \u201ca market follower,\u201d Fischler said, but he called it strategically important as the company shifts innovation toward interoperability across devices. He argued core devices like anesthesia machines and ventilators are mature and increasingly commoditized, making connectivity and integrated workflows an important future differentiator.<\/p>\n<\/p><\/div>\n \u2192 With Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?<\/a><\/p>\n As an example, Fischler described the company\u2019s \u201cSilent ICU\u201d concept built on an open, bidirectional device-communication standard developed under IEEE. In the setup he described, Dr\u00e4ger devices\u2014including ventilators and patient monitors\u2014connect with infusion pumps from B. Braun and alarm systems from Ascom. The system routes alarms out of the patient room to caregivers\u2019 handheld devices or central stations, which Fischler said can improve patient healing by keeping rooms quieter and can enhance workflow efficiency by reducing unnecessary room entries and enabling caregivers to review and silence alarms remotely.<\/p>\n In the Q&A, Fischler cautioned that Silent ICU is \u201ca future topic\u201d and that single products in this area will not contribute meaningfully to near-term sales and earnings. Instead, he framed it as an enabler that supports sales of Dr\u00e4ger\u2019s core devices that are \u201cSDC-ready\u201d and \u201cfuture-proof\u201d through compatibility with the protocol.<\/p>\n Turning to Safety, Fischler said the division serves a broader set of industries, with major verticals including firefighters, oil and gas, chemical, and mining\u2014together representing around 50% to 60% of Safety net sales\u2014while the remainder comes from a wide range of other end markets. Key product categories include self-contained breathing apparatuses, gas detection sensors, personal protective equipment, and related offerings. Compared with Medical, Safety aftersales is smaller at roughly 20% to 25%, he said.<\/p>\n Fischler also emphasized defense as an increasingly important growth driver. He said Dr\u00e4ger supplies law enforcement and defense customers, especially NATO clients, offering both industrial products and specialized defense equipment such as filters for military vehicles, vessels, and aircraft, along with sensors capable of detecting chemical warfare gases.<\/p>\n He said Dr\u00e4ger believes it can grow its defense business to about \u20ac300 million of net sales by 2028. For 2025, Fischler reported net sales rising from below \u20ac100 million to above \u20ac100 million, while order intake grew \u201ceven a lot stronger,\u201d reflecting long lead times in defense procurement. He cited the example of work connected to planned Bundeswehr vessels, where delays in shipbuilding decisions can affect suppliers downstream, and described defense growth as \u201cback-end loaded.\u201d<\/p>\n Fischler said 2025 was a \u201cvery strong year,\u201d with record net sales and roughly 5% currency-adjusted growth. EBIT margin rose to 6.7%, and free cash flow increased by \u20ac16 million to \u20ac140 million, which he said supported strong share price performance.<\/p>\n He also detailed operational improvements despite headwinds. Fischler noted that 2024 EBIT had benefited from one-off gains\u2014including the sale of non-strategic business units and properties\u2014totaling \u20ac22 million, which did not recur in 2025. In addition, he cited negative impacts of \u20ac45 million from currencies and \u20ac25 million from U.S. tariffs, totaling \u20ac70 million of headwinds. Against that backdrop, Fischler said Dr\u00e4ger delivered \u20ac90 million of operational EBIT improvement in 2025, calling it the strongest year he has seen since joining the company in 2012, excluding the \u201cabnormal COVID years.\u201d<\/p>\n He reiterated a profitability-first focus announced after supply chain challenges in 2022, including a target to expand EBIT margin by an average of one percentage point per year over the coming years. With 2025\u2019s 6.7% margin, he said Dr\u00e4ger is \u201ca little bit ahead of target.\u201d<\/p>\n On capital returns, Fischler said Dr\u00e4ger will increase its dividend again\u2014by about 10%\u2014to \u201cabove \u20ac2,\u201d representing a payout ratio of 30% of earnings. He attributed the increase in part to a strong equity ratio of above 50%.<\/p>\n For 2026, Fischler said the company expects net sales growth of 2% to 6% on a currency-adjusted basis, corresponding to 1% to 5% nominal growth, and anticipates FX headwinds of roughly one percentage point. The EBIT margin outlook is 5% to 7.5%. He acknowledged that, based on the midpoint, this would not imply margin expansion, noting that 2025 benefited from favorable mix and a strong year-end that may not repeat. Still, he said Dr\u00e4ger is working toward further margin improvement and remains committed to margin expansion over the medium term.<\/p>\n Asked about the biggest drivers of margin improvement, Fischler cited three primary levers:<\/p>\n Top-line growth<\/p>\n<\/li>\n Continued \u201cprice enforcement,\u201d though he said it has become more difficult as inflation fades<\/p>\n<\/li>\n Cost discipline, including plans for no headcount increase in administrative functions in L\u00fcbeck<\/p>\n<\/li>\n<\/ul>\n On competitive dynamics in medical software, Fischler said hospitals are weighing open ecosystems versus proprietary systems. He said Dr\u00e4ger\u2019s open ecosystem roadmap can be a \u201ccompelling proposition\u201d and has helped win tenders, though he added that some customers may still prefer \u201cclosed shop\u201d ecosystems.<\/p>\n In gas detection, Fischler said Dr\u00e4ger faces competition from established suppliers such as Honeywell and MSA, and argued Dr\u00e4ger\u2019s differentiation includes sophisticated sensor technology across many gases and reliability that reduces false alarms\u2014an important factor for customers seeking quality and process stability.<\/p>\n Dr\u00e4gerwerk AG & Co KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection.<\/p>\n\n